12 research outputs found
Pathological and morphological properties of chronic gastroduodenitis in children with connective tissue dysplasia
Abstract
Collagen metabolic disorder affects morphological changes of mucosal-cellular barrier determining clinically-aided reparation processes. Morphologic assessment enables personalized approaches to handle inflammatory processes in upper gastro-intestinal tract (GIT) associated with extracellular matrix disorders.
Aim: examining patho-morphologic properties of gastric and duodenal mucosa in children with CGD associated with CTD.
Materials and methods. Morphologic examination of endoscopic biopsies in 63 children, 11-17 years old. Samples were processed by hematoxylin eosin section staining. The influence of dysplasia and patientβs response to standard therapy on morphological changes were assessed using odd ratio statistics, confidence limits, and p-values.
Results. Dependency of morphological changes versus the CTD degree and patient response to standard therapy: foci of fibrosis OR=7 and 5,25, eosin infiltration OR=3,684 and 3,667, dystrophic epithelium changes OR=2,344 and 3,023, change in glands architectonics OR=3,684 and 3,279, respectively. Biopsy samples from patients with CTD and weak therapy response feature dense lymphocyte-plasmocyte infiltration of gland epithelium and lamina propria (81,3%), pronounced diffuse edema (68,8%), and uneven gland localization with changed architectonics and dystrophically modified epithelium (62,5%). 78,6% not therapy-responsive children without DCT have morphologically pronounced CGD whereas irresponsiveness in children with the associated pathology isnβt strongly connected with CGD morphology.
Conclusion. Gastric and duodenal mucosa inflammation in children with expressed CTD features are characterized with lympho-histological infiltration of lamina propria and surface gland epithelium, increased edema, dystrophic changes of gland epithelium, and spread fibrosis loci indicating high risk of early chronicity and atrophic process formation. The account of clinical CTD conditions affecting pathogenic mucosal processes stipulates adequate CGD development assessment
ΠΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½Ρ ΠΎΡΠΎΠ±Π»ΠΈΠ²ΠΎΡΡΡ Ρ ΡΠΎΠ½ΡΡΠ½ΠΈΡ Π³Π°ΡΡΡΠΎΠ΄ΡΠΎΠ΄Π΅Π½ΡΡΡΠ² Ρ Π΄ΡΡΠ΅ΠΉ ΡΠ· Π΄ΠΈΡΠΏΠ»Π°Π·ΡΡΡ ΡΠΏΠΎΠ»ΡΡΠ½ΠΎΡ ΡΠΊΠ°Π½ΠΈΠ½ΠΈ
Collagen metabolic disorder affects morphological changes of mucosal-cellular barrier determining clinically-aided reparation processes. Morphologic assessment enables personalized approaches to handle inflammatory processes in upper gastro-intestinal tract (GIT) associated with extracellular matrix disorders.Aim: examining patho-morphologic properties of gastric and duodenal mucosa in children with CGD associated with CTD.Materials and methods. Morphologic examination of endoscopic biopsies in 63 children, 11-17 years old. Samples were processed by hematoxylin eosin section staining. The influence of dysplasia and patientβs response to standard therapy on morphological changes were assessed using odd ratio statistics, confidence limits, and p-values.Results. Dependency of morphological changes versus the CTD degree and patient response to standard therapy: foci of fibrosis OR=7 and 5,25, eosin infiltration OR=3,684 and 3,667, dystrophic epithelium changes OR=2,344 and 3,023, change in glands architectonics OR=3,684 and 3,279, respectively. Biopsy samples from patients with CTD and weak therapy response feature dense lymphocyte-plasmocyte infiltration of gland epithelium and lamina propria (81,3%), pronounced diffuse edema (68,8%), and uneven gland localization with changed architectonics and dystrophically modified epithelium (62,5%). 78,6% not therapy-responsive children without DCT have morphologically pronounced CGD whereas irresponsiveness in children with the associated pathology isnβt strongly connected with CGD morphology.Conclusion. Gastric and duodenal mucosa inflammation in children with expressed CTD features are characterized with lympho-histological infiltration of lamina propria and surface gland epithelium, increased edema, dystrophic changes of gland epithelium, and spread fibrosis loci indicating high risk of early chronicity and atrophic process formation. The account of clinical CTD conditions affecting pathogenic mucosal processes stipulates adequate CGD development assessment.Β Β Β Β Β ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΈ Π»Π΅ΡΠ΅Π±Π½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ² ΠΏΡΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
Π³Π°ΡΡΡΠΎΠ΄ΡΠΎΠ΄Π΅Π½ΠΈΡΠ°Ρ
(Π₯ΠΠ) Ρ Π΄Π΅ΡΠ΅ΠΉ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅ΡΡΡ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π΄Π΅ΡΠ΅ΠΊΡΠ° ΡΠΈΠ½ΡΠ΅Π·Π° ΠΊΠΎΠ»Π»Π°Π³Π΅Π½Π°, ΡΡΠΎ Π»Π΅ΠΆΠΈΡ Π² ΠΎΡΠ½ΠΎΠ²Π΅ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π° Π΄ΠΈΡΠΏΠ»Π°Π·ΠΈΠΈ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ (ΠΠ‘Π’). ΠΠ°ΡΡΡΠ΅Π½ΠΈΠ΅ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΠ·ΠΌΠ° ΠΊΠΎΠ»Π»Π°Π³Π΅Π½Π° ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΌΡΠΊΠΎΡΠΈΠ»ΠΈΠ°ΡΠ½ΠΎΠ³ΠΎ Π±Π°ΡΡΠ΅ΡΠ°, ΠΊΠΎΡΠΎΡΡΠ΅ Π²Π»ΠΈΡΡΡ Π½Π° ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π·Π°ΡΠΈΡΠ½ΡΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ² ΡΠ΅ΠΏΠ°ΡΠ°ΡΠΈΠΈ. ΠΠ°ΠΆΠ½ΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΈΠΌΠ΅Π΅Ρ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΡΠ΅Π½ΠΊΠ° ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΡΠ»ΠΈΠ·ΠΈΡΡΠΎΠΉ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° (Π‘ΠΠ) ΠΈ Π΄Π²Π΅Π½Π°Π΄ΡΠ°ΡΠΈΠΏΠ΅ΡΡΡΠ½ΠΎΠΉ ΠΊΠΈΡΠΊΠΈ (ΠΠΠ) Π΄Π»Ρ ΠΏΠ΅ΡΡΠΎΠ½ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Π° ΠΊ Π²ΡΠ±ΠΎΡΡ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ°ΠΊΡΠΈΠΊΠΈ ΠΏΡΠΈ Π₯ΠΠ, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΌ Ρ ΠΠ‘Π’.Π¦Π΅Π»Ρ ΡΠ°Π±ΠΎΡΡ β ΠΎΡΠ΅Π½ΠΈΡΡ ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π‘ΠΠ¨ ΠΈ ΠΠΠ Ρ Π΄Π΅ΡΠ΅ΠΉ Ρ Π₯ΠΠ, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΌ Ρ ΠΠ‘Π’.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ½Π΄ΠΎΡΠΊΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΡ
Π±ΠΈΠΎΠΏΡΠ°ΡΠΎΠ² ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° ΠΈ ΠΠΠ Ρ 63 Π΄Π΅ΡΠ΅ΠΉ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 11 Π΄ΠΎ 17 Π»Π΅Ρ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΎΠ±ΡΠ°Π±ΠΎΡΠ°Π½ ΠΏΠΎ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠ΅ Ρ ΠΎΠΊΡΠ°ΡΠΊΠΎΠΉ Π³Π΅ΠΌΠ°ΡΠΎΠΊΡΠΈΠ»ΠΈΠ½βΡΠΎΠ·ΠΈΠ½ΠΎΠΌ ΠΈ ΠΏΠΎ ΠΠ°Π½ ΠΠΈΠ·ΠΎΠ½Ρ. Π‘ΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· Π²ΠΊΠ»ΡΡΠ°Π» ΡΠ°ΡΡΠ΅Ρ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΡΠ°Π½ΡΠΎΠ², Π΄ΠΎΠ²Π΅ΡΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΈΠ½ΡΠ΅ΡΠ²Π°Π»ΠΎΠ² ΠΈ p-Π·Π½Π°ΡΠ΅Π½ΠΈΡ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ ΠΎΡ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΠΠ‘Π’ ΠΈ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π½Π° ΠΏΡΠΎΡΠΎΠΊΠΎΠ»ΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ: ΠΎΡΠ°Π³ΠΈ ΡΠΈΠ±ΡΠΎΠ·Π° OR = 7,00 ΠΈ 5,25, ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΡ ΡΠΎΠ·ΠΈΠ½ΠΎΡΠΈΠ»Π°ΠΌΠΈ OR = 3,68 ΠΈ 3,67, Π΄ΠΈΡΡΡΠΎΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΠΏΠΈΡΠ΅Π»ΠΈΡ OR = 2,34 ΠΈ 3,02, ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π°ΡΡ
ΠΈΡΠ΅ΠΊΡΠΎΠ½ΠΈΠΊΠΈ ΠΆΠ΅Π»Π΅Π· OR = 3,68 ΠΈ 3,28 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΠ΅ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΌΡ ΠΎΡΠ²Π΅ΡΡ Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΏΡΠΈΡΡΡΠ° ΠΏΠ»ΠΎΡΠ½Π°Ρ Π»ΠΈΠΌΡΠΎΡΠΈΡΠ°ΡΠ½ΠΎ-ΠΏΠ»Π°Π·ΠΌΠΎΡΠΈΡΠ°ΡΠ½Π°Ρ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΡ ΡΠΏΠΈΡΠ΅Π»ΠΈΡ ΠΆΠ΅Π»Π΅Π· ΠΈ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΠ»Π°ΡΡΠΈΠ½ΠΊΠΈ (81,3 %), Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΡΠΉ Π΄ΠΈΡΡΡΠ·Π½ΡΠΉ ΠΎΡΠ΅ΠΊ (68,8 %), Π½Π΅ΡΠ°Π²Π½ΠΎΠΌΠ΅ΡΠ½ΠΎΡΡΡ Π·ΠΎΠ½ ΡΠ°ΡΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ ΠΆΠ΅Π»Π΅Π· Ρ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ Π°ΡΡ
ΠΈΡΠ΅ΠΊΡΠΎΠ½ΠΈΠΊΠΈ ΠΈ Π΄ΠΈΡΡΡΠΎΡΠΈΡΠ΅ΡΠΊΠΈ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½ΡΠΌ ΡΠΏΠΈΡΠ΅Π»ΠΈΠ΅ΠΌ (62,5 %). ΠΡΡΠ°ΠΆΠ΅Π½Π½ΡΠ΅ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΎΡΠΌΠ΅ΡΠ΅Π½Ρ Ρ 78,6 % Π΄Π΅ΡΠ΅ΠΉ Π±Π΅Π· ΠΠ‘Π’, ΠΊΠΎΡΠΎΡΡΠ΅ Π½Π΅ ΠΎΡΠ²Π΅ΡΠ°ΡΡ Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡ, Ρ
ΠΎΡΡ ΠΏΡΠΈ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΠΎΡΠ²Π΅ΡΠ° Π½Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π½Π΅ ΠΈΠΌΠ΅Π΅Ρ ΡΠ΅ΡΠΊΠΎΠΉ ΡΠ²ΡΠ·ΠΈ Ρ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΠΌΠΎΠΉ Π₯ΠΠ.ΠΡΠ²ΠΎΠ΄Ρ. ΠΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΏΡΠΎΡΠ΅ΡΡΡ Π‘ΠΠ¨ ΠΈ ΠΠΠ Ρ Π΄Π΅ΡΠ΅ΠΉ Ρ ΠΠ‘Π’ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΡΡ Π»ΠΈΠΌΡΠΎΠ³ΠΈΡΡΠΈΠΎΡΠΈΡΠ°ΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠ΅ΠΉ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΠ»Π°ΡΡΠΈΠ½ΠΊΠΈ, ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΠ½ΠΎΠ³ΠΎ ΡΠΏΠΈΡΠ΅Π»ΠΈΡ ΠΈ ΡΠΏΠΈΡΠ΅Π»ΠΈΡ ΠΆΠ΅Π»Π΅Π·, ΠΎΡΠ΅ΠΊΠΎΠΌ, Π΄ΠΈΡΡΡΠΎΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡΠΌΠΈ ΡΠΏΠΈΡΠ΅Π»ΠΈΡ ΠΆΠ΅Π»Π΅Π· ΠΈ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠΌΠΈ ΠΎΡΠ°Π³Π°ΠΌΠΈ ΡΠΈΠ±ΡΠΎΠ·Π°, ΡΡΠΎ ΠΏΠΎΠ²ΡΡΠ°Π΅Ρ ΡΠΈΡΠΊ ΡΠ°Π½Π½Π΅ΠΉ Ρ
ΡΠΎΠ½ΠΈΠ·Π°ΡΠΈΠΈ ΠΈ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π°ΡΡΠΎΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ². ΠΠ»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΈ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° Π₯ΠΠ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ ΡΡΠΈΡΡΠ²Π°ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ ΠΠ‘Π’, ΠΊΠΎΡΠΎΡΡΠ΅ Π²Π»ΠΈΡΡΡ Π½Π° ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΡΠ΅ΡΡΡ Π² ΡΠ»ΠΈΠ·ΠΈΡΡΠΎΠΉ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠ΅.Β ΠΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡΡΡ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΡΠ²Π°Π½Π½Ρ ΠΏΠ΅ΡΠ΅Π±ΡΠ³Ρ Ρ
Π²ΠΎΡΠΎΠ±ΠΈ ΡΠ° Π»ΡΠΊΡΠ²Π°Π»ΡΠ½ΠΈΡ
Π·Π°ΡΠΎΠ±ΡΠ² ΠΏΡΠΈ Ρ
ΡΠΎΠ½ΡΡΠ½ΠΈΡ
Π³Π°ΡΡΡΠΎΠ΄ΡΠΎΠ΄Π΅Π½ΡΡΠ°Ρ
(Π₯ΠΠ) Ρ Π΄ΡΡΠ΅ΠΉ Π²ΠΈΠ·Π½Π°ΡΠ°ΡΡΡΡΡ Π½Π°ΡΠ²Π½ΡΡΡΡ Π³Π΅Π½Π΅ΡΠΈΡΠ½ΠΎΠ³ΠΎ Π΄Π΅ΡΠ΅ΠΊΡΡ ΡΠΈΠ½ΡΠ΅Π·Ρ ΠΊΠΎΠ»Π°Π³Π΅Π½Ρ, ΡΠΎ Π»Π΅ΠΆΠΈΡΡ Π² ΠΎΡΠ½ΠΎΠ²Ρ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Ρ Π΄ΠΈΡΠΏΠ»Π°Π·ΡΡ ΡΠΏΠΎΠ»ΡΡΠ½ΠΎΡ ΡΠΊΠ°Π½ΠΈΠ½ΠΈ (ΠΠ‘Π’). ΠΠΎΡΡΡΠ΅Π½Π½Ρ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΡΠ·ΠΌΡ ΠΊΠΎΠ»Π°Π³Π΅Π½Ρ ΡΠΏΡΠΈΡΠΈΠ½ΡΡ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½Ρ Π·ΠΌΡΠ½ΠΈ ΠΌΡΠΊΠΎΡΠΈΠ»ΡΠ°ΡΠ½ΠΎΠ³ΠΎ Π±Π°ΡβΡΡΠ°, ΡΠΊΡ Π²ΠΏΠ»ΠΈΠ²Π°ΡΡΡ Π½Π° ΠΊΠ»ΡΠ½ΡΡΠ½ΠΈΠΉ ΠΏΠ΅ΡΠ΅Π±ΡΠ³ Π·Π°Ρ
Π²ΠΎΡΡΠ²Π°Π½Π½Ρ, ΠΌΠΎΠ΄ΡΠ»ΡΠ²Π°Π½Π½Ρ Π·Π°Ρ
ΠΈΡΠ½ΠΈΡ
ΡΠ°ΠΊΡΠΎΡΡΠ² Ρ ΠΏΡΠΎΡΠ΅ΡΡΠ² ΡΠ΅ΠΏΠ°ΡΠ°ΡΡΡ. ΠΠ°ΠΆΠ»ΠΈΠ²Π΅ Π·Π½Π°ΡΠ΅Π½Π½Ρ ΠΌΠ°Ρ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½Π΅ ΠΎΡΡΠ½ΡΠ²Π°Π½Π½Ρ ΡΡΠ°Π½Ρ ΡΠ»ΠΈΠ·ΠΎΠ²ΠΎΡ ΠΎΠ±ΠΎΠ»ΠΎΠ½ΠΊΠΈ ΡΠ»ΡΠ½ΠΊΠ° (Π‘ΠΠ¨) ΡΠ° Π΄Π²Π°Π½Π°Π΄ΡΡΡΠΈΠΏΠ°Π»ΠΎΡ ΠΊΠΈΡΠΊΠΈ (ΠΠΠ) Π΄Π»Ρ ΠΏΠ΅ΡΡΠΎΠ½ΡΡΡΠΊΠΎΠ²Π°Π½ΠΎΠ³ΠΎ ΠΏΡΠ΄Ρ
ΠΎΠ΄Ρ Π΄ΠΎ Π²ΠΈΠ±ΠΎΡΡ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ½ΠΎΡ ΡΠ°ΠΊΡΠΈΠΊΠΈ ΠΏΡΠΈ Π₯ΠΠ, ΡΠΎ Π°ΡΠΎΡΡΡΡΡΡΡΡ Π· ΠΠ‘Π’.ΠΠ΅ΡΠ° ΡΠΎΠ±ΠΎΡΠΈ β ΠΎΡΡΠ½ΠΈΡΠΈ ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½Ρ ΠΎΡΠΎΠ±Π»ΠΈΠ²ΠΎΡΡΡ Π‘ΠΠ¨ Ρ ΠΠΠ Ρ Π΄ΡΡΠ΅ΠΉ ΡΠ· Π₯ΠΠ, ΡΠΊΠΈΠΉ Π°ΡΠΎΡΡΠΉΠΎΠ²Π°Π½ΠΈΠΉ ΡΠ· ΠΠ‘Π’.ΠΠ°ΡΠ΅ΡΡΠ°Π»ΠΈ ΡΠ° ΠΌΠ΅ΡΠΎΠ΄ΠΈ. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½Ρ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π΅Π½Π΄ΠΎΡΠΊΠΎΠΏΡΡΠ½ΠΈΡ
Π±ΡΠΎΠΏΡΠ°ΡΡΠ² ΡΠ»ΡΠ½ΠΊΠ° ΡΠ° ΠΠΠ Ρ 63 Π΄ΡΡΠ΅ΠΉ Π²ΡΠΊΠΎΠΌ Π²ΡΠ΄ 11 Π΄ΠΎ 17 ΡΠΎΠΊΡΠ². ΠΠ°ΡΠ΅ΡΡΠ°Π» ΠΎΠΏΡΠ°ΡΡΠ²Π°Π»ΠΈ Π·Π° Π³ΡΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΎΡ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠΎΡ Π· Π·Π°Π±Π°ΡΠ²Π»Π΅Π½Π½ΡΠΌ Π³Π΅ΠΌΠ°ΡΠΎΠΊΡΠΈΠ»ΡΠ½βΠ΅ΠΎΠ·ΠΈΠ½ΠΎΠΌ Ρ Π·Π° ΠΠ°Π½ ΠΡΠ·ΠΎΠ½ΠΎΠΌ. Π‘ΡΠ°ΡΠΈΡΡΠΈΡΠ½ΠΈΠΉ Π°Π½Π°Π»ΡΠ· Π²ΠΊΠ»ΡΡΠ°Π² ΡΠΎΠ·ΡΠ°Ρ
ΡΠ½ΠΎΠΊ Π²ΡΠ΄Π½ΠΎΡΠ΅Π½Π½Ρ ΡΠ°Π½ΡΡΠ², Π΄ΠΎΠ²ΡΡΡΠΈΡ
ΡΠ½ΡΠ΅ΡΠ²Π°Π»ΡΠ² Ρ p-Π·Π½Π°ΡΠ΅Π½Π½Ρ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΠΈ. ΠΡΡΠ°Π½ΠΎΠ²ΠΈΠ»ΠΈ Π·Π°Π»Π΅ΠΆΠ½ΡΡΡΡ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΡ
Π·ΠΌΡΠ½ Π²ΡΠ΄ Π²ΠΈΡΠ°ΠΆΠ΅Π½ΠΎΡΡΡ ΠΠ‘Π’ Ρ ΡΠ΅Π°ΠΊΡΡΡ Π½Π° ΠΏΡΠΎΡΠΎΠΊΠΎΠ»ΡΠ½Ρ ΡΠ΅ΡΠ°ΠΏΡΡ: Π²ΠΎΠ³Π½ΠΈΡΠ° ΡΡΠ±ΡΠΎΠ·Ρ OR = 7,00 Ρ 5,25, ΡΠ½ΡΡΠ»ΡΡΡΠ°ΡΡΡ Π΅ΠΎΠ·ΠΈΠ½ΠΎΡΡΠ»Π°ΠΌΠΈ OR = 3,68 ΡΠ° 3,67, Π΄ΠΈΡΡΡΠΎΡΡΡΠ½Ρ Π·ΠΌΡΠ½ΠΈ Π΅ΠΏΡΡΠ΅Π»ΡΡ OR = 2,34 ΡΠ° 3,02, Π·ΠΌΡΠ½Π° Π°ΡΡ
ΡΡΠ΅ΠΊΡΠΎΠ½ΡΠΊΠΈ Π·Π°Π»ΠΎΠ· OR = 3,68 ΡΠ° 3,28 Π²ΡΠ΄ΠΏΠΎΠ²ΡΠ΄Π½ΠΎ. ΠΠ΅Π΅ΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΉ Π²ΡΠ΄ΠΏΠΎΠ²ΡΠ΄Ρ Π½Π° ΡΠ΅ΡΠ°ΠΏΡΡ ΠΏΡΠΈΡΠ°ΠΌΠ°Π½Π½Π° ΡΡΠ»ΡΠ½Π° Π»ΡΠΌΡΠΎΡΠΈΡΠ°ΡΠ½ΠΎ-ΠΏΠ»Π°Π·ΠΌΠΎΡΠΈΡΠ°ΡΠ½Π° ΡΠ½ΡΡΠ»ΡΡΡΠ°ΡΡΡ Π΅ΠΏΡΡΠ΅Π»ΡΡ Π·Π°Π»ΠΎΠ· Ρ Π²Π»Π°ΡΠ½ΠΎΡ ΠΏΠ»Π°ΡΡΠΈΠ½ΠΊΠΈ (81,3 %), Π²ΠΈΡΠ°ΠΆΠ΅Π½ΠΈΠΉ Π΄ΠΈΡΡΠ·Π½ΠΈΠΉ Π½Π°Π±ΡΡΠΊ (68,8 %), Π½Π΅ΡΡΠ²Π½ΠΎΠΌΡΡΠ½Π΅ ΡΠΎΠ·ΡΠ°ΡΡΠ²Π°Π½Π½Ρ Π·Π°Π»ΠΎΠ· Π·Ρ Π·ΠΌΡΠ½ΠΎΡ Π°ΡΡ
ΡΡΠ΅ΠΊΡΠΎΠ½ΡΠΊΠΈ ΡΠ° Π΄ΠΈΡΡΡΠΎΡΡΡΠ½ΠΎ Π·ΠΌΡΠ½Π΅Π½ΠΈΠΌ Π΅ΠΏΡΡΠ΅Π»ΡΡΠΌ (62,5 %). ΠΠΈΡΠ°ΠΆΠ΅Π½Ρ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½Ρ Π·ΠΌΡΠ½ΠΈ ΠΌΠ°ΡΡΡ 78,6 % Π΄ΡΡΠ΅ΠΉ Π±Π΅Π· ΠΠ‘Π’, ΡΠΊΡ Π½Π΅ Π²ΡΠ΄ΠΏΠΎΠ²ΡΠ΄Π°ΡΡΡ Π½Π° ΡΠ΅ΡΠ°ΠΏΡΡ, Ρ
ΠΎΡΠ° ΠΏΡΠΈ Π°ΡΠΎΡΡΠΉΠΎΠ²Π°Π½ΡΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΡΡ Π²ΡΠ΄ΡΡΡΠ½ΡΡΡΡ Π²ΡΠ΄ΠΏΠΎΠ²ΡΠ΄Ρ Π½Π° Π»ΡΠΊΡΠ²Π°Π½Π½Ρ Π½Π΅ ΠΌΠ°Ρ ΡΡΡΠΊΠΎΠ³ΠΎ Π·Π²βΡΠ·ΠΊΡ Π· ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΎΡ ΡΠΎΡΠΌΠΎΡ Π₯ΠΠ.ΠΠΈΡΠ½ΠΎΠ²ΠΊΠΈ. ΠΠ°ΠΏΠ°Π»ΡΠ½Ρ ΠΏΡΠΎΡΠ΅ΡΠΈ Π‘ΠΠ¨ Ρ ΠΠΠ Ρ Π΄ΡΡΠ΅ΠΉ ΡΠ· ΠΠ‘Π’ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΡΡΡ Π»ΡΠΌΡΠΎΠ³ΡΡΡΡΠΎΡΠΈΡΠ°ΡΠ½ΠΎΡ ΡΠ½ΡΡΠ»ΡΡΡΠ°ΡΡΡΡ Π²Π»Π°ΡΠ½ΠΎΡ ΠΏΠ»Π°ΡΡΠΈΠ½ΠΊΠΈ, ΠΏΠΎΠ²Π΅ΡΡ
Π½Π΅Π²ΠΎΠ³ΠΎ Π΅ΠΏΡΡΠ΅Π»ΡΡ ΡΠ° Π΅ΠΏΡΡΠ΅Π»ΡΡ Π·Π°Π»ΠΎΠ·, Π½Π°Π±ΡΡΠΊΠΎΠΌ, Π΄ΠΈΡΡΡΠΎΡΡΡΠ½ΠΈΠΌΠΈ Π·ΠΌΡΠ½Π°ΠΌΠΈ Π΅ΠΏΡΡΠ΅Π»ΡΡ Π·Π°Π»ΠΎΠ· Ρ ΠΏΠΎΡΠΈΡΠ΅Π½ΠΈΠΌΠΈ Π²ΠΎΠ³Π½ΠΈΡΠ°ΠΌΠΈ ΡΡΠ±ΡΠΎΠ·Ρ, ΡΠΎ ΠΏΡΠ΄Π²ΠΈΡΡΡ ΡΠΈΠ·ΠΈΠΊ ΡΠ°Π½Π½ΡΠΎΡ Ρ
ΡΠΎΠ½ΡΠ·Π°ΡΡΡ, ΡΠΎΡΠΌΡΠ²Π°Π½Π½Ρ Π°ΡΡΠΎΡΡΡΠ½ΠΈΡ
ΠΏΡΠΎΡΠ΅ΡΡΠ². ΠΠ»Ρ ΠΎΡΡΠ½ΡΠ²Π°Π½Π½Ρ ΠΏΠ΅ΡΠ΅Π±ΡΠ³Ρ, ΠΏΡΠΎΠ³Π½ΠΎΠ·Ρ Π₯ΠΠ Π½Π΅ΠΎΠ±Ρ
ΡΠ΄Π½ΠΎ Π²ΡΠ°Ρ
ΡΠ²Π°Π½Π½Ρ ΠΊΠ»ΡΠ½ΡΡΠ½ΠΈΡ
ΠΎΠ·Π½Π°ΠΊ ΠΠ‘Π’, ΠΊΠΎΡΡΡ Π²ΠΏΠ»ΠΈΠ²Π°ΡΡΡ Π½Π° ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ½Ρ ΠΏΡΠΎΡΠ΅ΡΠΈ Ρ ΡΠ»ΠΈΠ·ΠΎΠ²ΡΠΉ ΠΎΠ±ΠΎΠ»ΠΎΠ½ΡΡ.
Immuno-histochemical features of chronic gastro-duodenitis in children with connective tissue dysplasia
Aim of the work: Better predicting the outcome of chronic gastro-duodenitis (CGD) and plan therapeutic intervention in children with connective tissue dysplasia (CTD) requires the accurate account of the pathological processes associated with CTD. Evaluations of histochemical and immune-histochemical changes in the small intestinal (SI) and stomach mucosa, particularly changes in collagen IV expression, improve the diagnostics of chronic CGD and predicting the disease outcome, providing a rationale for therapy approaches.
The aim of research: to define histochemical and immuno-histochemical characteristics of stomach and duodenal mucus in children with CGD combined with CTD.
Materials and methods. Stomach and SI biopsies from 63 children with CTD were examined using histological, histochemical and immune-histochemical approaches. Collagen Type IV (Ab-3) expression in each group was measured indirectly via streptavidin-peroxidase assay (Thermo Scientific), while the content of neutral glycosaminoglycanes was examined by PAS-staining.
Results. Most patients without CTD have elevated PAS-reaction OR=7,0 (CI 1,14β42,971), when 87.5 % of children with CGD on a CTD background show significant decrease or absence of PAS-positive staining. The highest number of children with PAS-negative staining was identified in the groups with pronounced CTD. In children with the combined pathologies, the intensity of Collagen IV expression in BM of surface and glandular epithelium is 1.72 times (Ρ=0.003) higher than in children without dysplasia while its spread is also 1.6 times higher (Ρ=0.009)
Conclusions. The greatest number of children having PAS-negative staining was found in a group with well manifested CTD, which reflects the changes in saliva production, the decrease in mucins and mucoids, and also changes in physicochemical properties of the mucus that lead to a true mucus dystrophy. In children having CGD combined with CTD, the Collagen IV expression in BM of surface and glandular epithelium is 1.72 times higher than in children without dysplasia, while its spread is 1.6 times higher. This indicates the damage of epithelial and endothelial BM and is one of the major causes of fibrosis development
ΠΠ»ΡΠ½ΡΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½Ρ ΠΎΡΠΎΠ±Π»ΠΈΠ²ΠΎΡΡΡ Π°Π»Π΅ΡΠ³ΡΡΠ½ΠΎΠ³ΠΎ Π΅Π½ΡΠ΅ΡΠΎΠΊΠΎΠ»ΡΡΡ Π² Π΄ΡΡΠ΅ΠΉ ΡΠ°Π½Π½ΡΠΎΠ³ΠΎ Π²ΡΠΊΡ
Β The purpose was to study the clinical and morphological features of allergic enterocolitis in young children.Material and methods. 29 patients aged from 2 months to 2 years with severe allergic enterocolitis, who underwent endoscopic examination with targeted biopsy of the intestinal mucosa, were treated.Β For comparison of morphological, histochemical and immunohistochemical features, intestinal mucosal biopsies of children of the same age with gastrointestinal disorders, caused by protracted or chronic course of non-specific non-ulcer process in the intestine, were used. Immunohistochemical studies were performed on serial paraffin sections in accordance with standard protocols using Ab68 (Macrophage Marker) Ab-3 (Clone KP1), IgA (Heavy Chain) Ab-2, IgE (Epsilon-Heavy Chain) Ab-1 monoclonal antibodies and Imaging Ultra Vision Quanto Detection System HRP DAB (USA).Results. The debut of gastrointestinal symptoms in young children with allergic enterocolitis was observed in the first months of life and was characterized by vomiting or persistent regurgitations, intense griping, diarrhea with large amounts of mucus and/or blood, and delayed physical development. Presence of inflammatory process of intestinal mucosa with eosinophilic infiltration was morphologically established. According to immunohistochemical study, expression of CD68-macrophages and increased expression of IgA and IgE in the duodenal mucosa were detected.Conclusions. The diagnosis of allergic enterocolitis at an early age is complicated by the absence of specific clinical gastrointestinal symptoms and non-informative allergic examination (IgE-independent mechanism of inflammation), which may require morphological study to verify the diagnosis. Morphologically, in the examined patients, not only the presence of inflammatory process of the mucous membrane of the intestine with expressed eosinophilic infiltration is established, but also the immunohistochemistry data revealed the increased expression of CD68-macrophages, IgA and IgE in the mucous membrane of the duodenum, indicating the activation of both cellular and local humoral immunity.Β Β Π¦Π΅Π»Ρ ΡΠ°Π±ΠΎΡΡ β ΠΈΠ·ΡΡΠΈΡΡ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π°Π»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ½ΡΠ΅ΡΠΎΠΊΠΎΠ»ΠΈΡΠ° Ρ Π΄Π΅ΡΠ΅ΠΉ ΡΠ°Π½Π½Π΅Π³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ°.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ»Π΅ΡΠ΅Π½Ρ 29 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 2 ΠΌΠ΅ΡΡΡΠ΅Π² Π΄ΠΎ 2 Π»Π΅Ρ Ρ ΡΡΠΆΠ΅Π»ΡΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ Π°Π»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ½ΡΠ΅ΡΠΎΠΊΠΎΠ»ΠΈΡΠ°, ΠΊΠΎΡΠΎΡΡΠΌ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΎ ΡΠ½Π΄ΠΎΡΠΊΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Ρ ΠΏΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π±ΠΈΠΎΠΏΡΠΈΠ΅ΠΉ ΡΠ»ΠΈΠ·ΠΈΡΡΠΎΠΉ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ°. ΠΠ»Ρ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
, Π³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ Π±ΠΈΠΎΠΏΡΠ°ΡΡ ΡΠ»ΠΈΠ·ΠΈΡΡΠΎΠΉ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ° Π΄Π΅ΡΠ΅ΠΉ Π°Π½Π°Π»ΠΎΠ³ΠΈΡΠ½ΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° Ρ Π³Π°ΡΡΡΠΎΠΈΠ½ΡΠ΅ΡΡΠΈΠ½Π°Π»ΡΠ½ΡΠΌΠΈ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²Π°ΠΌΠΈ, ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½Π½ΡΠΌΠΈ Π·Π°ΡΡΠΆΠ½ΡΠΌ ΠΈΠ»ΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ Π½Π΅ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π½Π΅ΡΠ·Π²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° Π² ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ΅. ΠΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Ρ Π½Π° ΡΠ΅ΡΠΈΠΉΠ½ΡΡ
ΠΏΠ°ΡΠ°ΡΠΈΠ½ΠΎΠ²ΡΡ
ΡΡΠ΅Π·Π°Ρ
Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ ΡΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΡΠΌΠΈ ΠΏΡΠΎΡΠΎΠΊΠΎΠ»Π°ΠΌΠΈ Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½ΡΡ
Π°Π½ΡΠΈΡΠ΅Π» CD68 (Macrophage Marker) Ab-3 (Clone KP1), Π°Π½ΡΠΈΡΠ΅Π» IgA (Heavy Chain) Ab-2, IgE (epsilon-Heavy Chain) Ab-1 ΠΈ ΡΠΈΡΡΠ΅ΠΌΡ Π²ΠΈΠ·ΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ Ultra Vision Quanto Detectson System HRP DAB (USA).Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ΅Π±ΡΡ Π³Π°ΡΡΡΠΎΠΈΠ½ΡΠ΅ΡΡΠΈΠ½Π°Π»ΡΠ½ΡΡ
ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ² Ρ Π΄Π΅ΡΠ΅ΠΉ ΡΠ°Π½Π½Π΅Π³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° Ρ Π°Π»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ½ΡΠ΅ΡΠΎΠΊΠΎΠ»ΠΈΡΠΎΠΌ ΠΎΡΠΌΠ΅ΡΠ΅Π½ Ρ ΠΏΠ΅ΡΠ²ΡΡ
ΠΌΠ΅ΡΡΡΠ΅Π² ΠΆΠΈΠ·Π½ΠΈ, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΎΠ²Π°Π»ΡΡ ΡΠ²ΠΎΡΠΎΠΉ ΠΈΠ»ΠΈ ΡΡΠΎΠΉΠΊΠΈΠΌΠΈ ΡΡΡΠ³ΠΈΠ²Π°Π½ΠΈΡΠΌΠΈ, ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΡΠΌΠΈ ΠΊΠΎΠ»ΠΈΠΊΠ°ΠΌΠΈ, Π΄ΠΈΠ°ΡΠ΅Π΅ΠΉ Ρ ΠΏΡΠΈΠΌΠ΅ΡΡΡ Π±ΠΎΠ»ΡΡΠΎΠ³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° ΡΠ»ΠΈΠ·ΠΈ ΠΈ/ΠΈΠ»ΠΈ ΠΊΡΠΎΠ²ΠΈ, Π·Π°Π΄Π΅ΡΠΆΠΊΠΎΠΉ ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ°Π·Π²ΠΈΡΠΈΡ. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ Π½Π°Π»ΠΈΡΠΈΠ΅ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° ΡΠ»ΠΈΠ·ΠΈΡΡΠΎΠΉ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ° Ρ ΡΠΎΠ·ΠΈΠ½ΠΎΡΠΈΠ»ΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠ΅ΠΉ. Π ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ CD68-ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ², IgA ΠΈ IgE Π² ΡΠ»ΠΈΠ·ΠΈΡΡΠΎΠΉ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠ΅ Π΄Π²Π΅Π½Π°Π΄ΡΠ°ΡΠΈΠΏΠ΅ΡΡΡΠ½ΠΎΠΉ ΠΊΠΈΡΠΊΠΈ.ΠΡΠ²ΠΎΠ΄Ρ. ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° Π°Π»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ½ΡΠ΅ΡΠΎΠΊΠΎΠ»ΠΈΡΠ° Π² ΡΠ°Π½Π½Π΅ΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ Π·Π°ΡΡΡΠ΄Π½Π΅Π½Π° ΠΈΠ·-Π·Π° ΠΎΡΡΡΡΡΡΠ²ΠΈΡ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
Π³Π°ΡΡΡΠΎΠΈΠ½ΡΠ΅ΡΡΠΈΠ½Π°Π»ΡΠ½ΡΡ
ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ² ΠΈ Π½Π΅ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΠΎΡΡΠΈ Π°Π»Π»Π΅ΡΠ³ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ (IgE-Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΡΠΉ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ), ΡΡΠΎ ΡΡΠ΅Π±ΡΠ΅Ρ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π΄Π»Ρ Π²Π΅ΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΠ·Π°. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ Ρ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ Π½Π°Π»ΠΈΡΠΈΠ΅ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ ΡΠ»ΠΈΠ·ΠΈΡΡΠΎΠΉ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ° ΠΈ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΡ ΡΠΎΠ·ΠΈΠ½ΠΎΡΠΈΠ»Π°ΠΌΠΈ, Π° ΠΏΠΎ Π΄Π°Π½Π½ΡΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΠΈ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ CD68-ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ², IgA ΠΈ IgE Π² ΡΠ»ΠΈΠ·ΠΈΡΡΠΎΠΉ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠ΅ Π΄Π²Π΅Π½Π°Π΄ΡΠ°ΡΠΈΠΏΠ΅ΡΡΡΠ½ΠΎΠΉ ΠΊΠΈΡΠΊΠΈ, ΡΡΠΎ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ ΠΎΠ± Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΊΠ°ΠΊ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ, ΡΠ°ΠΊ ΠΈ ΠΌΠ΅ΡΡΠ½ΠΎΠ³ΠΎ Π³ΡΠΌΠΎΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ°.Β Β ΠΠ΅ΡΠ° ΡΠΎΠ±ΠΎΡΠΈ β Π²ΠΈΠ²ΡΠΈΡΠΈ ΠΊΠ»ΡΠ½ΡΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½Ρ ΠΎΡΠΎΠ±Π»ΠΈΠ²ΠΎΡΡΡ Π°Π»Π΅ΡΠ³ΡΡΠ½ΠΎΠ³ΠΎ Π΅Π½ΡΠ΅ΡΠΎΠΊΠΎΠ»ΡΡΡ Π² Π΄ΡΡΠ΅ΠΉ ΡΠ°Π½Π½ΡΠΎΠ³ΠΎ Π²ΡΠΊΡ.ΠΠ°ΡΠ΅ΡΡΠ°Π»ΠΈ ΡΠ° ΠΌΠ΅ΡΠΎΠ΄ΠΈ. ΠΡΠΎΠ»ΡΠΊΡΠ²Π°Π»ΠΈ 29 ΠΏΠ°ΡΡΡΠ½ΡΡΠ² Π²ΡΠΊΠΎΠΌ Π²ΡΠ΄ 2 ΠΌΡΡΡΡΡΠ² Π΄ΠΎ 2 ΡΠΎΠΊΡΠ² ΡΠ· Π²Π°ΠΆΠΊΠΈΠΌ ΠΏΠ΅ΡΠ΅Π±ΡΠ³ΠΎΠΌ Π°Π»Π΅ΡΠ³ΡΡΠ½ΠΎΠ³ΠΎ Π΅Π½ΡΠ΅ΡΠΎΠΊΠΎΠ»ΡΡΡ, ΡΠΊΠΈΠΌ Π²ΠΈΠΊΠΎΠ½Π°Π»ΠΈ Π΅Π½Π΄ΠΎΡΠΊΠΎΠΏΡΡΠ½Π΅ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π· ΠΏΡΠΈΡΡΠ»ΡΠ½ΠΎΡ Π±ΡΠΎΠΏΡΡΡΡ ΡΠ»ΠΈΠ·ΠΎΠ²ΠΎΡ ΠΎΠ±ΠΎΠ»ΠΎΠ½ΠΊΠΈ ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ°. ΠΠ»Ρ ΠΏΠΎΡΡΠ²Π½ΡΠ½Π½Ρ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΡ
, Π³ΡΡΡΠΎΡ
ΡΠΌΡΡΠ½ΠΈΡ
ΡΠ° ΡΠΌΡΠ½ΠΎΠ³ΡΡΡΠΎΡ
ΡΠΌΡΡΠ½ΠΈΡ
ΠΎΡΠΎΠ±Π»ΠΈΠ²ΠΎΡΡΠ΅ΠΉ Π²ΠΈΠΊΠΎΡΠΈΡΡΠΎΠ²ΡΠ²Π°Π»ΠΈ Π±ΡΠΎΠΏΡΠ°ΡΠΈ ΡΠ»ΠΈΠ·ΠΎΠ²ΠΎΡ ΠΎΠ±ΠΎΠ»ΠΎΠ½ΠΊΠΈ ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ° Π΄ΡΡΠ΅ΠΉ Π°Π½Π°Π»ΠΎΠ³ΡΡΠ½ΠΎΠ³ΠΎ Π²ΡΠΊΡ Π· Π³Π°ΡΡΡΠΎΡΠ½ΡΠ΅ΡΡΠΈΠ½Π°Π»ΡΠ½ΠΈΠΌΠΈ ΡΠΎΠ·Π»Π°Π΄Π°ΠΌΠΈ, ΡΠΎ Π·ΡΠΌΠΎΠ²Π»Π΅Π½Ρ ΡΡΠΈΠ²Π°Π»ΠΈΠΌ ΡΠΈ Ρ
ΡΠΎΠ½ΡΡΠ½ΠΈΠΌ ΠΏΠ΅ΡΠ΅Π±ΡΠ³ΠΎΠΌ Π½Π΅ΡΠΏΠ΅ΡΠΈΡΡΡΠ½ΠΎΠ³ΠΎ Π½Π΅Π²ΠΈΡΠ°Π·ΠΊΠΎΠ²ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡ Π² ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΡ.ΠΠΌΡΠ½ΠΎΠ³ΡΡΡΠΎΡ
ΡΠΌΡΡΠ½Ρ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π²ΠΈΠΊΠΎΠ½Π°Π»ΠΈ Π½Π° ΡΠ΅ΡΡΠΉΠ½ΠΈΡ
ΠΏΠ°ΡΠ°ΡΡΠ½ΠΎΠ²ΠΈΡ
Π·ΡΡΠ·Π°Ρ
Π²ΡΠ΄ΠΏΠΎΠ²ΡΠ΄Π½ΠΎ Π΄ΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΈΡ
ΠΏΡΠΎΡΠΎΠΊΠΎΠ»ΡΠ², Π·Π°ΡΡΠΎΡΠΎΠ²ΡΡΡΠΈ ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½Ρ Π°Π½ΡΠΈΡΡΠ»Π° CD68 (Macrophage Marker) Ab-3 (Clone KP1), Π°Π½ΡΠΈΡΡΠ»Π° IgA (Heavy Chain) Ab-2, IgE (epsilon-Heavy Chain) Ab-1 ΡΠ° ΡΠΈΡΡΠ΅ΠΌΡ Π²ΡΠ·ΡΠ°Π»ΡΠ·Π°ΡΡΡ Ultra Vision Quanto Detectson System HRP DAB (USA). Π Π΅Π·ΡΠ»ΡΡΠ°ΡΠΈ. ΠΠ΅Π±ΡΡ Π³Π°ΡΡΡΠΎΡΠ½ΡΠ΅ΡΡΠΈΠ½Π°Π»ΡΠ½ΠΈΡ
ΡΠΈΠΌΠΏΡΠΎΠΌΡΠ² Ρ Π΄ΡΡΠ΅ΠΉ ΡΠ°Π½Π½ΡΠΎΠ³ΠΎ Π²ΡΠΊΡ Π· Π°Π»Π΅ΡΠ³ΡΡΠ½ΠΈΠΌ Π΅Π½ΡΠ΅ΡΠΎΠΊΠΎΠ»ΡΡΠΎΠΌ Π²ΠΈΡΠ²Π»ΡΠ»ΠΈ Π² ΠΏΠ΅ΡΡΡ ΠΌΡΡΡΡΡ ΠΆΠΈΡΡΡ, Π²ΡΠ½ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΠ²Π°Π²ΡΡ Π±Π»ΡΠ²ΠΎΡΠΎΡ Π°Π±ΠΎ ΡΡΡΠΉΠΊΠΈΠΌΠΈ Π·ΡΠΈΠ³ΡΠ²Π°Π½Π½ΡΠΌΠΈ, ΡΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΈΠΌΠΈ ΠΊΠΎΠ»ΡΠΊΠ°ΠΌΠΈ, Π΄ΡΠ°ΡΠ΅ΡΡ Π· Π΄ΠΎΠΌΡΡΠΊΠ°ΠΌΠΈ Π²Π΅Π»ΠΈΠΊΠΎΡ ΠΊΡΠ»ΡΠΊΠΎΡΡΡ ΡΠ»ΠΈΠ·Ρ ΡΠ°/Π°Π±ΠΎ ΠΊΡΠΎΠ²Ρ, Π·Π°ΡΡΠΈΠΌΠΊΠΎΡ ΡΡΠ·ΠΈΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠ·Π²ΠΈΡΠΊΡ. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΎ Π²ΡΡΠ°Π½ΠΎΠ²ΠΈΠ»ΠΈ Π½Π°ΡΠ²Π½ΡΡΡΡ Π·Π°ΠΏΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡ ΡΠ»ΠΈΠ·ΠΎΠ²ΠΎΡ ΠΎΠ±ΠΎΠ»ΠΎΠ½ΠΊΠΈ ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ° ΡΠ° ΡΡ Π΅ΠΎΠ·ΠΈΠ½ΠΎΡΡΠ»ΡΠ½Ρ ΡΠ½ΡΡΠ»ΡΡΡΠ°ΡΡΡ. Π£ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠΌΡΠ½ΠΎΠ³ΡΡΡΠΎΡ
ΡΠΌΡΡΠ½ΠΎΠ³ΠΎ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π²ΠΈΡΠ²ΠΈΠ»ΠΈ ΠΏΡΠ΄Π²ΠΈΡΠ΅Π½Ρ Π΅ΠΊΡΠΏΡΠ΅ΡΡΡ CD68-ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΡΠ², IgA ΡΠ° IgE Ρ ΡΠ»ΠΈΠ·ΠΎΠ²ΡΠΉ ΠΎΠ±ΠΎΠ»ΠΎΠ½ΡΡ Π΄Π²Π°Π½Π°Π΄ΡΡΡΠΈΠΏΠ°Π»ΠΎΡ ΠΊΠΈΡΠΊΠΈ.ΠΠΈΡΠ½ΠΎΠ²ΠΊΠΈ. ΠΡΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° Π°Π»Π΅ΡΠ³ΡΡΠ½ΠΎΠ³ΠΎ Π΅Π½ΡΠ΅ΡΠΎΠΊΠΎΠ»ΡΡΡ Π² ΡΠ°Π½Π½ΡΠΎΠΌΡ Π²ΡΡΡ ΡΡΠΊΠ»Π°Π΄Π½Π΅Π½Π° Π²ΡΠ΄ΡΡΡΠ½ΡΡΡΡ ΡΠΏΠ΅ΡΠΈΡΡΡΠ½ΠΈΡ
ΠΊΠ»ΡΠ½ΡΡΠ½ΠΈΡ
Π³Π°ΡΡΡΠΎΡΠ½ΡΠ΅ΡΡΠΈΠ½Π°Π»ΡΠ½ΠΈΡ
ΡΠΈΠΌΠΏΡΠΎΠΌΡΠ² Ρ Π½Π΅ΡΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΡΡΡΡ Π°Π»Π΅ΡΠ³ΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΎΠ³ΠΎ ΠΎΠ±ΡΡΠ΅ΠΆΠ΅Π½Π½Ρ (IgE-Π½Π΅Π·Π°Π»Π΅ΠΆΠ½ΠΈΠΉ ΠΌΠ΅Ρ
Π°Π½ΡΠ·ΠΌ ΡΠΎΠ·Π²ΠΈΡΠΊΡ Π·Π°ΠΏΠ°Π»Π΅Π½Π½Ρ), ΡΠΎ ΠΌΠΎΠΆΠ΅ ΠΏΠΎΡΡΠ΅Π±ΡΠ²Π°ΡΠΈ Π·Π΄ΡΠΉΡΠ½Π΅Π½Π½Ρ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΎΠ³ΠΎ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π΄Π»Ρ Π²Π΅ΡΠΈΡΡΠΊΠ°ΡΡΡ Π΄ΡΠ°Π³Π½ΠΎΠ·Ρ. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΎ Π² ΠΎΠ±ΡΡΠ΅ΠΆΠ΅Π½ΠΈΡ
Ρ
Π²ΠΎΡΠΈΡ
Π²ΡΡΠ°Π½ΠΎΠ²ΠΈΠ»ΠΈ Π½Π°ΡΠ²Π½ΡΡΡΡ Π·Π°ΠΏΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡ ΡΠ»ΠΈΠ·ΠΎΠ²ΠΎΡ ΠΎΠ±ΠΎΠ»ΠΎΠ½ΠΊΠΈ ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ° Π·Ρ Π·Π½Π°ΡΠ½ΠΎΡ ΡΠ½ΡΡΠ»ΡΡΡΠ°ΡΡΡΡ Π΅ΠΎΠ·ΠΈΠ½ΠΎΡΡΠ»Π°ΠΌΠΈ, Π·Π° Π΄Π°Π½ΠΈΠΌΠΈ ΡΠΌΡΠ½ΠΎΠ³ΡΡΡΠΎΡ
ΡΠΌΡΡ Π²ΠΈΡΠ²ΠΈΠ»ΠΈ ΠΏΡΠ΄Π²ΠΈΡΠ΅Π½Ρ Π΅ΠΊΡΠΏΡΠ΅ΡΡΡ CD68-ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΡΠ², IgA ΡΠ° IgE Ρ ΡΠ»ΠΈΠ·ΠΎΠ²ΡΠΉ ΠΎΠ±ΠΎΠ»ΠΎΠ½ΡΡ Π΄Π²Π°Π½Π°Π΄ΡΡΡΠΈΠΏΠ°Π»ΠΎΡ ΠΊΠΈΡΠΊΠΈ, ΡΠΎ Π²ΠΊΠ°Π·ΡΡ Π½Π° Π°ΠΊΡΠΈΠ²Π°ΡΡΡ ΡΠΊ ΠΊΠ»ΡΡΠΈΠ½Π½ΠΎΠ³ΠΎ, ΡΠ°ΠΊ Ρ ΠΌΡΡΡΠ΅Π²ΠΎΠ³ΠΎ Π³ΡΠΌΠΎΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΌΡΠ½ΡΡΠ΅ΡΡ
ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½Ρ ΡΠ° ΡΠΌΡΠ½ΠΎΠ³ΡΡΡΠΎΡ ΡΠΌΡΡΠ½Ρ ΠΎΡΠΎΠ±Π»ΠΈΠ²ΠΎΡΡΡ ΠΏΠ»Π°ΡΠ΅Π½ΡΠ°ΡΠ½ΠΎ-Π΅Π½Π΄ΠΎΠΌΠ΅ΡΡΡΠ°Π»ΡΠ½ΠΈΡ ΡΡΡΡΠΊΡΡΡ ΠΏΡΠΈ Π΄ΠΎΠ±ΡΠΎΡΠΊΡΡΠ½ΠΈΡ Ρ Π·Π»ΠΎΡΠΊΡΡΠ½ΠΈΡ ΠΏΡΡ Π»ΠΈΠ½Π°Ρ Ρ ΠΆΡΠ½ΠΎΠΊ
Aim. Researchmaterials were the placenta of women operated on papillary carcinoma (encapsulated), endometrium of women with the same tumor markers detected in the placenta, this endometrium were taken during diagnosing postpartum catamnesis of the state of reproductive health, in comparison to the endometrium of women with benign uterine tumors (leiomyoma).Methods and results. Methods, that were used in the study: histological, immunohistochemical β indirect streptavidin-peroxidase method for detecting the expression of Ki67 Clon MIB-1, p53 Clon: DO-7, REA, Cytoceratina AE1 / AE3; Vimentin Clone: v9, receptors for estrogen (RE) and progesterone (RP). The study evaluated predictors of placental-endometrial disorders in women with cancer pathology: elevation of relative amount of expression of proliferative marker Ki-67 and p53 tumor marker in the placenta and endometrium, leading to violations in the structure of the process of regeneration; dischronosis in levels of expression of estrogen and progesterone receptors in the endometrium; presence of CEA expression in 25% of women of the main group in the endometrium and placenta; atypical glandular hyperplasia, endometrial polyps and micropolyps were found, which are important in the development of oncologic pathology.Π‘ ΡΠ΅Π»ΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠΎΠ² ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΎΡΡΠΎΡΠ½ΠΈΠΉ Π² ΠΏΠ»Π°ΡΠ΅Π½ΡΠ΅ ΠΈ ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΠΈ ΠΆΠ΅Π½ΡΠΈΠ½, ΠΏΡΠΎΠΎΠΏΠ΅ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρ ΡΠ°ΠΊΠ° ΡΠΈΡΠΎΠ²ΠΈΠ΄Π½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, Π²ΡΠΏΠΎΠ»Π½ΠΈΠ»ΠΈ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠ»Π°ΡΠ΅Π½Ρ ΠΈ ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΡ ΠΆΠ΅Π½ΡΠΈΠ½, ΠΊΠΎΡΠΎΡΡΠΌ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠ²Π½ΠΎΠ΅ Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ²ΠΎ Π² ΡΠ²ΡΠ·ΠΈ Ρ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ ΠΏΠ°ΠΏΠΈΠ»Π»ΡΡΠ½ΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ (ΠΈΠ½ΠΊΠ°ΠΏΡΡΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ), ΠΈ ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΡ ΠΎΡ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ Π΄ΠΎΠ±ΡΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ ΠΎΠΏΡΡ
ΠΎΠ»ΡΠΌΠΈ ΠΌΠ°ΡΠΊΠΈ (Π»Π΅ΠΉΠΎΠΌΠΈΠΎΠΌΠ°). Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ ΠΎΠ±ΡΠ΅Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄Ρ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΌΠ΅ΡΠΎΠ΄ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Ρ ΠΠΠΠ’ Ki67 Clon MIB-1, Ρ53 Clon DO-7, Π EA, CytoΡeratina AE1/AE3, Vimentin Clone v9, ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠ² ΠΊ ΡΡΡΡΠΎΠ³Π΅Π½Π°ΠΌ ΠΈ ΠΏΡΠΎΠ³Π΅ΡΡΠ΅ΡΠΎΠ½Ρ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΡ ΠΏΠ»Π°ΡΠ΅Π½ΡΠ°ΡΠ½ΠΎ-ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΠ°Π»ΡΠ½ΠΈΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ ΠΏΡΠΈ ΠΎΠ½ΠΊΠΎΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ Ρ ΠΆΠ΅Π½ΡΠΈΠ½: ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΎΠ±ΡΠ΅ΠΌΠ° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π² ΠΏΠ»Π°ΡΠ΅Π½ΡΠ΅ ΠΈ ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΠΈ ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠΊΠ΅ΡΠ° ΠΡ-67 ΠΈ ΠΎΠ½ΠΊΠΎΠΌΠ°ΡΠΊΠ΅ΡΠ° Ρ53, ΡΡΠΎ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ² ΡΠ΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΠΈ; Π΄ΠΈΡΡ
ΡΠΎΠ½ΠΎΠ· ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠ² ΡΡΡΡΠΎΠ³Π΅Π½ΠΎΠ² ΠΈ ΠΏΡΠΎΠ³Π΅ΡΡΠ΅ΡΠΎΠ½Π° Π² ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΠΈ; Π½Π°Π»ΠΈΡΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π ΠΠ Ρ 25% ΠΆΠ΅Π½ΡΠΈΠ½ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ ΠΊΠ°ΠΊ Π² ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΠΈ, ΡΠ°ΠΊ ΠΈ Π² ΠΏΠ»Π°ΡΠ΅Π½ΡΠ΅; Π½Π°Π»ΠΈΡΠΈΠ΅ Π°ΡΠΈΠΏΠΈΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·ΠΈΡΡΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΠΏΠ»Π°Π·ΠΈΠΈ, ΠΏΠΎΠ»ΠΈΠΏΠΎΠ·Π° ΠΈ ΠΌΠΈΠΊΡΠΎΠΏΠΎΠ»ΠΈΠΏΠΎΠ·Π° ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΡ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΈΠΌΠ΅ΡΡ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ ΠΎΠ½ΠΊΠΎΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ.Π ΠΌΠ΅ΡΠΎΡ Π²ΠΈΠ·Π½Π°ΡΠ΅Π½Π½Ρ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΡΠ² ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΡ
ΡΡΠ°Π½ΡΠ² Ρ ΠΏΠ»Π°ΡΠ΅Π½ΡΡ ΡΠ° Π΅Π½Π΄ΠΎΠΌΠ΅ΡΡΡΡ ΠΆΡΠ½ΠΎΠΊ, ΡΠΊΠΈΡ
ΠΏΡΠΎΠΎΠΏΠ΅ΡΡΠ²Π°Π»ΠΈ Π· ΠΏΡΠΈΠ²ΠΎΠ΄Ρ ΡΠ°ΠΊΡ ΡΠΈΡΠΎΠ²ΠΈΠ΄Π½ΠΎΡ Π·Π°Π»ΠΎΠ·ΠΈ, Π·Π΄ΡΠΉΡΠ½ΠΈΠ»ΠΈ ΠΏΠΎΡΡΠ²Π½ΡΠ»ΡΠ½Π΅ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ ΠΏΠ»Π°ΡΠ΅Π½Ρ ΡΠ° Π΅Π½Π΄ΠΎΠΌΠ΅ΡΡΡΡ ΠΆΡΠ½ΠΎΠΊ, ΡΠΊΠΈΠΌ Π·Π΄ΡΠΉΡΠ½ΠΈΠ»ΠΈ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠ²Π½Π΅ Π²ΡΡΡΡΠ°Π½Π½Ρ Ρ Π·Π²βΡΠ·ΠΊΡ Π· Π½Π°ΡΠ²Π½ΡΡΡΡ ΠΏΠ°ΠΏΡΠ»ΡΡΠ½ΠΎΡ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠΈ (ΡΠ½ΠΊΠ°ΠΏΡΡΠ»ΡΠΎΠ²Π°Π½ΠΎΡ), ΠΉ Π΅Π½Π΄ΠΎΠΌΠ΅ΡΡΡΡ Π²ΡΠ΄ ΠΆΡΠ½ΠΎΠΊ ΡΠ· Π΄ΠΎΠ±ΡΠΎΡΠΊΡΡΠ½ΠΈΠΌΠΈ ΠΏΡΡ
Π»ΠΈΠ½Π°ΠΌΠΈ ΠΌΠ°ΡΠΊΠΈ (Π»Π΅ΠΉΠΎΠΌΡΠΎΠΌΠ°). ΠΡΠΎΡΡΠ³ΠΎΠΌ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π²ΠΈΠΊΠΎΡΠΈΡΡΠ°Π»ΠΈ Π·Π°Π³Π°Π»ΡΠ½ΠΎΠ³ΡΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½Ρ ΠΌΠ΅ΡΠΎΠ΄ΠΈ, Π° ΡΠ°ΠΊΠΎΠΆ ΡΠΌΡΠ½ΠΎΠ³ΡΡΡΠΎΡ
ΡΠΌΡΡΠ½ΠΈΠΉ ΠΌΠ΅ΡΠΎΠ΄ Π²ΠΈΡΠ²Π»Π΅Π½Π½Ρ Π΅ΠΊΡΠΏΡΠ΅ΡΡΡ Π· ΠΠΠΠ’ Ki67 Clon MIB-1, Ρ53 Ρ53 Clon DO-7, Π EA, CytoΡeratina AE1/AE3, Vimentin Clone v9, ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΡΠ² Π΄ΠΎ Π΅ΡΡΡΠΎΠ³Π΅Π½ΡΠ² Ρ ΠΏΡΠΎΠ³Π΅ΡΡΠ΅ΡΠΎΠ½Ρ. ΠΡΡΠ°Π½ΠΎΠ²ΠΈΠ»ΠΈ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠΈ ΠΏΠ»Π°ΡΠ΅Π½ΡΠ°ΡΠ½ΠΎ-Π΅Π½Π΄ΠΎΠΌΠ΅ΡΡΡΠ°Π»ΡΠ½ΠΈΡ
ΠΏΠΎΡΡΡΠ΅Π½Ρ ΠΏΡΠΈ ΠΎΠ½ΠΊΠΎΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΡΡ Ρ ΠΆΡΠ½ΠΎΠΊ: Π·Π±ΡΠ»ΡΡΠ΅Π½Π½Ρ Π²ΡΠ΄Π½ΠΎΡΠ½ΠΎΠ³ΠΎ ΠΎΠ±ΡΡΠ³Ρ Π΅ΠΊΡΠΏΡΠ΅ΡΡΡ Ρ ΠΏΠ»Π°ΡΠ΅Π½ΡΡ ΡΠ° Π΅Π½Π΄ΠΎΠΌΠ΅ΡΡΡΡ ΠΏΡΠΎΠ»ΡΡΠ΅ΡΠ°ΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠΊΠ΅ΡΠ° ΠΡ-67 ΡΠ° ΠΎΠ½ΠΊΠΎΠΌΠ°ΡΠΊΠ΅ΡΠ° Ρ53, ΡΠΎ ΠΏΡΠΈΠ·Π²ΠΎΠ΄ΠΈΡΡ Π΄ΠΎ ΠΏΠΎΡΡΡΠ΅Π½Π½Ρ ΠΏΡΠΎΡΠ΅ΡΡΠ² ΡΠ΅Π³Π΅Π½Π΅ΡΠ°ΡΡΡ; Π΄ΠΈΡΡ
ΡΠΎΠ½ΠΎΠ· ΠΏΠΎΠΊΠ°Π·Π½ΠΈΠΊΡΠ² Π΅ΠΊΡΠΏΡΠ΅ΡΡΡ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΡΠ² Π΄ΠΎ Π΅ΡΡΡΠΎΠ³Π΅Π½ΡΠ² Ρ ΠΏΡΠΎΠ³Π΅ΡΡΠ΅ΡΠΎΠ½Ρ Π² Π΅Π½Π΄ΠΎΠΌΠ΅ΡΡΡΡ; Π½Π°ΡΠ²Π½ΡΡΡΡ Π΅ΠΊΡΠΏΡΠ΅ΡΡΡ Π ΠΠ Ρ 25% ΠΆΡΠ½ΠΎΠΊ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΡ Π³ΡΡΠΏΠΈ ΡΠΊ Π² Π΅Π½Π΄ΠΎΠΌΠ΅ΡΡΡΡ, ΡΠ°ΠΊ Ρ Π² ΠΏΠ»Π°ΡΠ΅Π½ΡΡ; Π½Π°ΡΠ²Π½ΡΡΡΡ Π°ΡΠΈΠΏΠΎΠ²ΠΎΡ Π·Π°Π»ΠΎΠ·ΠΈΡΡΠΎΡ Π³ΡΠΏΠ΅ΡΠΏΠ»Π°Π·ΡΡ, ΠΏΠΎΠ»ΡΠΏΠΎΠ·Ρ ΡΠ° ΠΌΡΠΊΡΠΎΠΏΠΎΠ»ΡΠΏΠΎΠ·Ρ Π΅Π½Π΄ΠΎΠΌΠ΅ΡΡΡΡ, ΡΠΊΡ ΠΌΠ°ΡΡΡ Π·Π½Π°ΡΠ΅Π½Π½Ρ Π² ΡΠΎΠ·Π²ΠΈΡΠΊΡ ΠΎΠ½ΠΊΠΎΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΡΡ.
Morphological and immunohistochemical peculiarities of placental-endometrial structures in women with benign and malignant tumors
Aim. Researchmaterials were the placenta of women operated on papillary carcinoma (encapsulated), endometrium of women with the same tumor markers detected in the placenta, this endometrium were taken during diagnosing postpartum catamnesis of the state of reproductive health, in comparison to the endometrium of women with benign uterine tumors (leiomyoma).
Methods and results. Methods, that were used in the study: histological, immunohistochemical β indirect streptavidin-peroxidase method for detecting the expression of Ki67 Clon MIB-1, p53 Clon: DO-7, REA, Cytoceratina AE1 / AE3; Vimentin Clone: v9, receptors for estrogen (RE) and progesterone (RP). The study evaluated predictors of placental-endometrial disorders in women with cancer pathology: elevation of relative amount of expression of proliferative marker Ki-67 and p53 tumor marker in the placenta and endometrium, leading to violations in the structure of the process of regeneration; dischronosis in levels of expression of estrogen and progesterone receptors in the endometrium; presence of CEA expression in 25% of women of the main group in the endometrium and placenta; atypical glandular hyperplasia, endometrial polyps and micropolyps were found, which are important in the development of oncologic pathology
Development and Validation of Pomalidomide Determination in Human Plasma by HPLC-MS/MS Method
Introduction. B-cell malignancies of the plasma cell leads to the second most spread hematological malignancy disease, called multiple myeloma. Pomalidomide is used in case of previous multiple myeloma ineffective treatment. Pomalidomide is a thalidomide synthetic derived, approved as immunomodulatory drug by the Food and Drug Administration (FDA). Nowadays, detection of pomalidomide in blood plasma by high performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) is not spread. Moreover, the detection and the experimental setting accumulated data are varying greatly. This investigation provides development and validation of pomalidomide aiming to determine human blood plasma by HPLC-MS/MS method. The samples were processed by methanol protein precipitation.Aim. The aim of this study is to develop a method for the pomalidomide in human plasma by HPLC-MS/MS for pharmacokinetic studies.Materials and methods. Determination of pomalidomide in plasma by HPLC-MS/MS. The samples were processed by methanol protein precipitation.Results and discussion. This method was validated by next parameters: selectivity, matrix effect, calibration curve, accuracy, precision, spike recovery, lower limit of quantification, detection limit, carry-over and stability.Conclusion. The method of the determination of pomalidomide in human plasma was developed and validated by HPLC-MS/MS. The linearity in plasma sample was achieved in the concentration range of 1,00 β 500,00 ng/ml. Method could be applied to pomalidomide determination in plasma for PK and BE studies